The Puzzle of Pemetrexed

31 August 2017

In July 2017 the UK Supreme Court provided a spectacularly significant finale to the long running patent infringement court battle between Eli Lilly and Actavis.  The fight related to Lilly’s patent covering its branded product Alimta® – an anti-cancer treatment requiring pemetrexed disodium administered with vitamin B12 – and Actavis’ proposed products involving other pemetrexed compounds and vitamin B12. The Decision was so significant because the Supreme Court found patent infringement even though Actavis’ proposed products fell outside the literal scope of the patent claim.

The Puzzle of Pemetrexed

Click here to view the article on the Biotech and Money website.

Our Expert
Isobel Finnie
Isobel Finnie
Locations: London (UK)

Haseltine Lake - Cookie Disclaimer

Our website uses cookies to provide you with a better online experience. If you continue to use our site without changing your browser settings, we'll assume you are happy to receive cookies. Please read our Cookie policy for more information.